Therefore, the coordinated downregulation of TGF-β1 and its downstream functional marker Foxp3, observed both systemically and within the tumor tissue, strongly suggests that targeting this axis may constitute a core mechanism underlying the Treg-modulating and immune-remodeling effects of the combined therapy. The gene discussed is TGFB1; the disease is neoplasm.